IP Library Granted Patent US 10,240,176
Granted Patent B2
US 10,240,176 · App. 15/139,263 · Granted Mar 26, 2019

Compositions and methods for producing benzylisoquinoline alkaloids

Inventors: Christina D. Smolke (Menlo Park, CA); Kristy M. Hawkins (Oakland, CA)
Assignee: California Institute of Technology
C12P17/12C12N9/0022C12N9/0059C12N9/1007C12N9/1096C12N9/88C12N15/81C12P7/24C12P13/001C12P17/182
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,240,176
App. No.
15/139,263
Granted
Mar 26, 2019
Kind
B2
Abstract

The present invention relates to host cells that produce compounds that are characterized as benzylisoquinolines, as well as select precursors and intermediates thereof. The host cells comprise one, two or more heterologous coding sequences wherein each of the heterologous coding sequences encodes an enzyme involved in the metabolic pathway of a benzylisoquinoline, or its precursors or intermediates from a starting compound. The invention also relates to methods of producing the benzylisoquinoline, as well as select precursors and intermediates thereof by culturing the host cells under culture conditions that promote expression of the enzymes that produce the benzylisoquinoline or precursors or intermediates thereof.

Claims (25)

1. A method for the production of a benzylisoquinoline alkaloid-product, the method comprising:

culturing a plurality of engineered non-plant cells under conditions suitable for protein production, the plurality of engineered non-plant cells comprising a first engineered non-plant cell comprising a first heterologous coding sequence and a second engineered non-plant cell comprising a second heterologous coding sequence, wherein the first and second heterologous coding sequences encode a first and second enzyme, respectively, that are involved in a metabolic pathway that converts tyrosine into the benzylisoquinoline alkaloid product, wherein the first and second enzymes are operably connected along the metabolic pathway,

wherein the first enzyme involved in the metabolic pathway that produces the benzylisoquinoline alkaloid product catalyzes at least one reaction that is selected from the group consisting of: Tyrosine to L-DOPA; L-DOPA to Dopamine; 4-hydroxyphenylacetaldehyde and Dopamine to Norcoclaurine; Tyrosine to 4-hydroxyphenylpyruvate; and 4-hydroxyphenylpyruvate to 4-hydroxyphenylacetaldehyde, and

wherein the second enzyme involved in the metabolic pathway that produces the benzylisoquinoline alkaloid product catalyzes at least one reaction that is selected from the group consisting of: Norcoclaurine to Coclaurine; Coclaurine to N-Methylcoclaurine; N-Methylcoclaurine to 3′-hydroxy-N-methylcoclaurine; 3′-hydroxy-N-methylcoclaurine to Reticuline; Norlaudanosoline to 6-O-methyl-norlaudanosoline; 6-O-methyl-norlaudanosoline to 6-O-methyl laudanosoline; 6-O-methyl-laudanosoline to Reticuline; Reticuline to Laudanine; Reticuline to Scoulerine; Scoulerine to Tetrahydrocolumbamine; Tetrahydrocolumbamine to Canadine; Reticuline to Salutaridine; Salutaridine to Salutaridinol; Salutaridinol to Salutaridinol-7-O-acetate; and Salutaridinol-7-O-acetate to Thebaine,

wherein the first enzyme produces a first product selected from the group consisting of L-DOPA, Dopamine, Norcoclaurine, 4-hydroxyphenylpyruvate, and 4-hydroxyphenylacetaldehyde, and

wherein the first product is acted upon by one or more enzymes to produce a second product that is along a metabolic pathway to produce the benzylisoquinoline alkaloid product, wherein the one or more enzymes comprises the second enzyme, and wherein the second product is selected from the group consisting of: Coclaurine, N-Methylcoclaurine 3′-hydroxy-N-methylcoclaurine, Reticuline, 6-O-methyl-norlaudanosoline, 6-O-methyl-laudanosoline, Laudanine, Scoulerine, Tetrahydrocolumbamine, Canadine, Salutaridine, Salutaridinol, Salutaridinol-7-O-acetate, and Thebaine.

2. The method of claim 1 , wherein the one or more enzymes consists of the second enzyme.

3. The method of claim 1 , wherein the second product is the benzylisoquinoline alkaloid product.

4. The method of claim 1 , wherein the second product is acted upon by a second set of one or more enzymes to produce the benzylisoquinoline alkaloid product.

5. The method of claim 1 , wherein the second product is converted to the benzylisoquinoline alkaloid product.

6. The method of claim 1 , further comprising recovering the benzylisoquinoline alkaloid product from the cell culture.

7. The method of claim 1 , wherein the engineered non-plant cell is selected from the group consisting of microbial cells, insect cells, mammalian cells, bacterial cells, and yeast cells.

8. A method for the production of a benzylisoquinoline alkaloid product, the method comprising:

culturing a plurality of engineered non-plant cells under conditions suitable for protein production, the plurality of engineered non-plant cells comprising a first engineered non-plant cell comprising a first heterologous coding sequence, and a second engineered non-plant cell comprising a second and third heterologous coding sequence, wherein the first, second, and third heterologous coding sequences encode a first, second, and third enzyme, respectively, that are involved in a metabolic pathway that converts tyrosine into the benzylisoquinoline alkaloid product, wherein the first, second, and third enzymes are operably connected along the metabolic pathway,

wherein the first enzyme involved in the metabolic pathway that produces the benzylisoquinoline alkaloid product catalyzes at least one reaction that is selected from the group consisting of: Tyrosine to L-DOPA; L-DOPA to Dopamine; 4-hydroxyphenylacetaldehyde and Dopamine to Norcoclaurine; Tyrosine to 4-hydroxyphenylpyruvate; and 4-hydroxyphenylpyruvate to 4-hydroxyphenylacetaldehyde, and

wherein each of the second and third enzymes involved in the metabolic pathway that produces the benzylisoquinoline alkaloid product catalyzes at least one reaction that is selected from the group consisting of: Norcoclaurine to Coclaurine; Coclaurine to N-Methylcoclaurine; N-Methylcoclaurine to 3′-hydroxy-N-methylcoclaurine; 3′-hydroxy-N-methylcoclaurine to Reticuline; Norlaudanosoline to 6-O-methyl-norlaudanosoline; 6-O-methyl-norlaudanosoline to 6-O-methyl-laudanosoline; 6-O-methyl-laudanosoline to Reticuline; Reticuline to Laudanine; Reticuline to Scoulerine; Scoulerine to Tetrahydrocolumbamine; Tetrahydrocolumbamine to Canadine; Reticuline to Salutaridine; Salutaridine to Salutaridinol; Salutaridinol to Salutaridinol-7-O-acetate; and Salutaridinol-7-O-acetate to Thebaine,

wherein the first enzyme produces a first product selected from the group consisting of L-DOPA, Dopamine, Norcoclaurine, 4-hydroxyphenylpyruvate, and 4-hydroxyphenylacetaldehyde,

wherein the first product is acted upon by a first set of one or more enzymes to produce a second product, wherein the first set of one or more enzymes comprises the second enzyme, and wherein the second product is selected from the group consisting of: Coclaurine N-Methylcoclaurine, 3′-hydroxy-N-methylcoclaurine, Reticuline, 6-O-methyl-norlaudanosoline, 6-C)-methyl-laudanosoline, Laudanine, Scoulerine, Tetrahydrocolumbamine, Canadine, Salutaridine, Salutaridinol, Salutaridinol-7-O-acetate, and Thebaine, and

wherein the second product is acted upon by a second set of one or more enzymes to produce a third product that is along a metabolic pathway to produce the benzylisoquinoline alkaloid product, wherein the second set of one or more enzymes comprises the third enzyme, and wherein the third product is selected from the group consisting of: Coclaurine, N-Methylcoclaurine, 3′-hydroxy-N-methylcoclaurine, Reticuline, 6-O-methyl-norlaudanosoline, 6-O-methyl-laudanosoline, Laudanine, Scoulerine, Tetrahydrocolumbamine, Canadine, Salutaridine, Salutaridinol, Salutaridinol-7-O-acetate, and Thebaine.

9. The method of claim 8 , wherein the first set of one or more enzymes consists of the second enzyme, the second set of one or more enzymes consists of the third enzyme, or both.

10. The method of claim 8 , wherein the third product is the benzylisoquinoline alkaloid product.

11. The method of claim 8 , wherein the third product is acted upon by a third set of one or more enzymes to produce the benzylisoquinoline alkaloid product.

12. The method of claim 8 , wherein the third product is converted to the benzylisoquinoline alkaloid product.

13. The method of claim 8 , further comprising recovering the benzylisoquinoline alkaloid product from the cell culture.

14. The method of claim 8 , wherein the engineered non-plant cell is selected from the group consisting of microbial cells, insect cells, mammalian cells, bacterial cells, and yeast cells.

Assignments (3)
SECURITY INTEREST Recorded Aug 29, 2025
From: ANTHEIA, INC.
To: HERCULES CAPITAL, INC., AS AGENT
Reel/Frame 072750/0812 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 24, 2017
From: SMOLKE, CHRISTINA D.; HAWKINS, KRISTY
To: CALIFORNIA INSTITUTE OF TECHNOLOGY
Reel/Frame 041727/0577 →
CONFIRMATORY LICENSE Recorded Aug 9, 2016
From: CALIFORNIA INSTITUTE OF TECHNOLOGY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 039376/0247 →
Continuity (6)
Division 14961662 · Dec 7, 2015
Division 14614484 · Feb 5, 2015
Division 11875814 · Oct 19, 2007
Provisional Application 60859149 · Nov 15, 2006
Provisional Application 60852954 · Oct 19, 2006
Related Publication 20160319314A1 · Nov 3, 2016
Cited By (2)
US 12,480,131 US 12,497,638